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Diabetes mellitus (DM) is the most common cause of chronic kidney disease and end stage
renal disease. New onset diabetes mellitus after transplant (NODAT) has been described
in approximately 30% of non-diabetic kidney-transplant recipients many years post trans-
plantation. DM in patients with kidney transplantation constitutes a major comorbidity, and
has significant impact on the patients and allografts’ outcome. In addition to the major
comorbidity and mortality that result from cardiovascular and other DM complications,
long standing DM after kidney-transplant has significant pathological injury to the allograft,
which results in lowering the allografts and the patients’ survivals. In spite of the cumula-
tive body of data on diabetic nephropathy (DN) in the native kidney, there has been very
limited data on the DN in the transplanted kidney. In this review, we will shed the light on
the risk factors that lead to the development of NODAT. We will also describe the impact
of DM on the transplanted kidney, and the outcome of kidney-transplant recipients with
NODAT. Additionally, we will present the most acceptable data on management of NODAT.
Keywords: diabetes mellitus, diabetic nephropathy, kidney-transplant, podocyte, new onset of diabetes after
transplant, suPAR, mTORC1 signaling, B17 receptor
INTRODUCTION
As the epidemic of diabetes mellitus (DM) is growing, diabetic
nephropathy (DN) remains the leading cause of end stage renal
disease (ESRD) in the American population [US Renal Data Sys-
tem (USRDS) data 2012]. DN and ESRD as its consequence, poses
a major healthcare problem especially in developed countries, and
as such it represents a great financial burden to the society. In the
United States, over 21 million people, or 7% of the general pop-
ulation, are estimated to have diabetes. To date, despite aggressive
research conducted in the early diagnosis and treatment of DN,
the vast majority of diabetic patients eventually progress to ESRD.
For these patients, either dialysis or renal transplantation remain
the only options of survival.
Renal transplantation has been considered the therapy of choice
in suitable ESRD or pre-ESRD patients since it confers a better sur-
vival benefit to these patients compared to dialysis (1–3). Despite
renal transplantation addressing the problem of imminent renal
failure, DM and DN remain prevalent among kidney-transplant
patients leading in some cases to allograft loss and contributing
to overall patient’s mortality. DM may represent a sequela of the
preexisting condition leading to ESRD or can develop as de novo
after kidney or any other solid organ transplantation in transplant
recipients.
Diabetic nephropathy was the etiology of ESRD in approxi-
mately 23% of kidney-transplant recipients in the United States
in 2008 (4). These numbers unfortunately continue to grow as the
number of diabetic patients in the general population increases.
NEW ONSET OF DIABETES MELLITUS AFTER
KIDNEY-TRANSPLANT
The incidence of new onset diabetes mellitus after transplant
(NODAT) is variable, ranging between 10 and 46% depending
on the study design and the definition of NODAT (5–7). More
specifically, NODAT has been reported to occur in 4–25% of renal
transplant recipients, 2.5–25% of liver transplant recipients, 4–
40% of heart transplant recipients, and 30–35% of lung transplant
recipients (8–11). In order to establish more precise diagnosis of
NODAT, international consensus guidelines defined the criteria
for NODAT and these include the following: symptoms of diabetes
and random plasma glucose ≥200 mg/dL (11.1 mmol/L), fasting
plasma glucose ≥126 mg/dL (7.0 mmol/L), and 2-h plasma glu-
cose ≥200 mg/dL (11.1 mmol/L) during an oral glucose tolerance
test (8). If at any time point either of these criteria in post trans-
plant patient is met, the diagnosis of NODAT can be established.
Levels of glycosylated hemoglobin A1c are unreliable marker of
NODAT during the first three to six post transplant months, given
the fact that many chronic kidney disease (CKD) stage 5 and ESRD
patients are anemic at baseline when receiving a kidney-transplant.
Many patients undergo renal and other solid organ transplan-
tation, hence only a subgroup of patients will develop NODAT.
It remains poorly understood what predisposes this subgroup of
patients to the development of NODAT. The literature describes
various modifiable and non-modifiable risk factors for develop-
ment of NODAT. Non-modifiable risk factors include age, race,
genetic background, family history of diabetes, and previous glu-
cose intolerance. Modifiable risk factors are obesity, hepatitis C
virus (HCV), cytomegalovirus infections, and immunosuppres-
sive drugs (12, 13). The risk of NODAT development increases
with time from transplantation. Therefore, early detection and
prompt action are essential in reducing the risk of NODAT and its
complications (14).
Among the non-modifiable risk factors age is considered the
strongest risk factor for development of NODAT (6, 12, 15). A
study by Cosio et al. (7) that included 2078 allograft recipients,
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showed that individuals older than 45 were 2.9 times more likely to
develop NODAT. Data from the USRDS showed that first kidney-
transplant recipients with ages between 45 and 59 years had a
relative risk (RR) for NODAT of 1.9 (95% confidence interval
(CI) 1.73–2.09; P < 0.0001), whereas, individuals≥60 years had a
risk of 2.6 (95% CI 2.32–2.92; P < 0.0001) (12, 15). Age increased
the risk for development of diabetes 1.5-fold for every 10-year
increase in age (12, 16).
RISK FACTORS OF NODAT
Obesity represents a modifiable risk factor and has consistently
been shown to be strongly associated with development of NODAT
(6, 15, 17). Data from the USRDS revealed that obese patients (BMI
≥30 kg/m2) have an RR for NODAT of 1.73 (95% CI 1.57–1.90;
P < 0.0001), this being, along with age, one of the most consistent
risk factors (6, 12). The molecular mechanisms of obesity have
been studied in detail in the non-transplant population where
chronic inflammatory markers synthesis is upregulated. Adipose
tissue is known to produce adipocytokines, including leptin, tumor
necrosis factor alpha (TNF-α), interleukins, and adiponectin (18,
19). Activation of the TNF-α system has been associated with
insulin resistance through the generation of defects in the phos-
phorylation of the receptor and decreasing the expression of
insulin-sensitive glucose transporters. Induction of IL-6 synthe-
sis has been associated with alterations in glucose tolerance and
is possibly a predictor of DM2 (19, 20). Adiponectin is a 30-kDa,
collagen-like protein synthesized by adipocytes. High adiponectin
concentrations have been associated with an independent reduc-
tion in the risk of developing type 2 DM in a healthy population
(19, 21). In transplant recipients, a low pre-transplant serum con-
centration of adiponectin was described as an independent risk
factor for the development of NODAT (22). A recent study found
that for every 1µg/mL decrease in adiponectin concentration, the
risk of developing NODAT is increased by 13% (19).
Race also plays an important role with respect to NODAT
development. Even though most of the transplant centers through
out the world expose their patients to similar immunosuppres-
sive induction and maintenance protocols, African American and
Hispanic patients appear to have a significantly higher risk for
development of NODAT compared to Caucasians. Likely, genetic
polymorphisms among Black and Hispanic transplant recipients
allow for more common disease prevalence compared to their
Caucasian counterparts. These polymorphisms remain a subject
of research, however precise description is lacking in the transplant
literature.
Additionally, infections are also described as culprits of
NODAT. Transplanted patients at baseline are more susceptible
to infections than the general population. A chronic HCV infec-
tion (either acquired peri-operatively from the donor or present
in the recipient at the time of transplantation), especially in a
setting of uncontrolled viremia, poses a risk factor for NODAT
development. The USRDS registry confirmed that the 1-year inci-
dence of NODAT in HCV-positive patients at transplantation was
significantly higher compared to the HCV-negative patients (25.6
vs. 15.4%; P < 0.0001) (6), clearly demonstrating higher risk for
NODAT development in HCV carriers. Recent basic science stud-
ies have demonstrated that the HCV elicits an apoptosis-like death
of pancreatic beta-cells through endoplasmatic reticulum stress-
involved, Caspase 3-Dependent Pathway (23). Interferon has been
the drug of choice for treatment of hepatitis C infection in the non-
transplant population for several decades. Unfortunately, its use
in the HCV infected transplant patients has been widely avoided
due to its propensity to elicit acute rejection in the allograft. The
novel drugs (protease and nucleotide analog inhibitors) recently
released on the market for treatment of HCV infection in non-
transplanted patients are still lacking official FDA approval in the
transplant cohort. Their use in this cohort has been strictly off
label and transplant center dependent. Thus, their prime time for
this clinical indication is likely to come in the near future. It would
be interesting to see if this will have a positive impact on decreasing
the incidence of NODAT in the transplant recipients.
IMMUNOSUPPRESSION DRUGS
In addition to the above mentioned factors influencing NODAT
development, several immunosuppressive agents that are com-
monly used in the transplant arena have been noted to have
diabetogenic potential. Herein, commonly used drugs include glu-
cocorticoids, calcineurin inhibitors (CNIs) including tacrolimus
(TAC) and cyclosporine (CYC), as well as the mammalian target
of rapamycin (mTOR) inhibitors (sirolimus and everolimus). The
diabetogenic effect of all of these drugs has been explored in detail
and their effect on development of NODAT has been elucidated
in several major studies.
Glucocorticoids, as the oldest immunosuppressive agents, have
a strongest diabetogenic potential, which is dose dependent. The
predominant factor for causing PTDM by corticosteroids seems
to be the aggravation of insulin resistance, however, several studies
have displayed deleterious effects on insulin secretion and beta-
cells apoptosis (24). The precise mechanisms of glucocorticoid-
induced insulin resistance are not well understood. In vivo and
in vitro animal studies demonstrate initiation of glucocorticoid
related insulin signaling cascade in skeletal muscles, resulting in
reduced glucose uptake and glycogen synthesis (25, 26). In vitro,
the effect of glucocorticoids on β-cell lines has been studied in
detail. Glucocorticoids were shown to reduce the expression of
GLUT 2 and glucokinase, thereby impairing glucose-stimulated
insulin secretion (24, 26). Further, Dexamethasone was shown
to stimulate transcription of serum and glucocorticoid-inducible
kinase 1, upregulating the activity of voltage-gated K+ channels
and leading to reduced Ca2+ entry through voltage-gated Ca2+
channels with resultant decreased insulin release (26, 27). In iso-
lated rat islets, dexamethasone decreases the activation of protein
kinase C through inhibition of the diacylglycerol–phospholipase
C pathway (26, 28).
Additionally, there is some conflicting data regarding the ben-
efit of early corticosteroid withdrawal vs. steroid continuation
protocols with respect to NODAT manifestation.
A large randomized controlled study found that early steroid
withdrawal does not confer any significant advantage compared to
steroid continuation,with the remark that fewer patients with early
steroid withdrawal required insulin for NODAT at 5 years [4/107
(3.7%) vs. 10/86 (11.6%), P = 0.049] (29). On the other hand,
large retrospective study involving more than 25,000 transplant
recipients reported significant benefits of early steroid withdrawal
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when compared to a steroid-containing regimen with respect to
NODAT. The cumulative incidence of NODAT within 3 years
post-transplant was 12.3% in steroid-free vs. 17.7% in steroid-
containing regimens, P < 0.001. Overall, steroid-containing reg-
imens carried a 42% increased risk for NODAT at the time of
hospital discharge (30).
Calcineurin inhibitors are also commonly prescribed drugs in
the transplant arena. Both CYC and TAC administration corre-
lates strongly with NODAT development, however, TAC appears
to have more pronounced diabetogenic effect as demonstrated in
prospective and retrospective studies (31, 32). This was observed in
kidney, heart, liver, and lung transplants (24). Interestingly, some
of the basic science studies involving these agents are not fully
supportive of these clinical findings (33).
Calcineurin inhibitors induce NODAT by variety of mecha-
nisms, including decreased insulin secretion and a direct toxic
effect on the pancreatic beta-cells. The effect on beta-cells sur-
vival implicates the direct effect of CNIs on the nuclear factor
of activated T-cell (NFAT) signaling. CNIs regulate the dephos-
phorylation of (NFAT) protein and CREB (cAMP-responsive
element-binding transcription factor) activity-2 (TORC2). The
dephosphorylation of these proteins regulates several target genes
[insulin, Glut2, (pancreatic and duodenal homeobox 1 (Pdx-1),
insulin receptor substrate-2 (Irs2), cyclin D1, cyclin D2, cyclin-
dependent kinase 4 (CDK4), etc.], which are critical in β-cell
survival, replication, and function. TAC binds intracellularly to
FK506-binding protein 1B (FKBP1B) before docking in the cal-
cineurin binding site (Cnb1) of calcineurin, thus inhibiting cal-
cineurin and its downstream pathways and decreasing β-cell repli-
cation and survival (26). Moreover, CYC induces inhibition of cal-
cineurin activated leucine zipper-bearing-kinase, leading to beta
cell apoptosis (34). Further, mitochondria play a key role in the
insulin secretion mainly by providing ATP supply. CYC binds read-
ily to cyclophilin D in the mitochondrial permeability transition
pore and blocks the opening of this channel on the mitochondrion
and thereby reduces the cytoplasmic free-Ca2+ concentration thus
interfering with glucose-stimulated insulin secretion (26, 35).
Finally, even though with less frequency, mTOR inhibitors
continue to be used among transplant patients despite clinical evi-
dence of their use being associated with greater risks of allograft
failure and recipient death compared with a CNI-based regimen
(36). Additionally, mTOR inhibitors have been associated with sig-
nificant risk for NODAT development, especially in combination
therapy with TAC, thus with a tendency of sirolimus contributing
more to the NODAT development rather than TAC (37).
The effects of sirolimus on the function and survival of β-cells
appears paradoxical based on animal studies and vitro studies with
cell lines or human islets. In vitro sirolimus is noted to increase the
insulin content in human islet cells (38) as well the secretion in
both basal (50%) and stimulated (40%) states in mini pigs in vivo
(39). On the other hand, additional in vitro studies have shown that
sirolimus may facilitate the opening of ATP sensitive potassium
channels thereby impairing the insulin secretion (40) in addition
to suppressing the glucose-stimulated insulin secretion via direct
inhibition of Krebs cycle and decrease of mitochondrial ATP pro-
duction (41). Further, there is convincing evidence that sirolimus
may disrupt regeneration and proliferation of islets, most likely via
direct inhibition of the mTOR complex 1 (mTOR C1) signaling
and its downstream regulatory effect on cyclin-dependent kinase
4, ultimately leading to reduced cyclin D2 and D3, which are crit-
ical regulators of β-cell cycle, proliferation, and mass (38, 42). In
summary, the effects of sirolimus on insulin secretion remain the
subject of further investigation.
There are no data so far to indicate that mycophenolate and
azathioprine are involved in the development of NODAT.
DIABETIC NEPHROPATHY AFTER KIDNEY-TRANSPLANT
Diabetic nephropathy occurs in the transplanted kidney after
approximately 5.9 years (43), in patients with pre-transplant DM
and those who develop NODAT. In a study of 58 kidney-transplant
recipients, 74.1% had history of DM before kidney transplan-
tation and 25.9% had NODAT, of those whom DN histologic
findings developed, 69.6% were in patients with history of DM and
30.4% were in NODAT patients. The time from transplantation to
the development of DN was slightly longer in NODAT patients
(6.68± 3.86 vs. 9.93± 3.07 years, P = 0.05); however, as expected,
the duration of diabetes was similar in the two groups at the time
of histologic findings of DN (6.68± 3.86 vs. 5.90± 3.13 years,
P = 0.66) (43).
The pathological findings of DN post kidney transplantation
are in most part similar to those of typical DN in native kidneys.
Thickening of GBM and the tubular basement membrane consti-
tutes the first sign of DN. Mesangial matrix expansion develops
later on. The extracellular matrix accumulates over time and forms
nodular mesangial changes that gradually lead to the compression
of the associated glomerular capillaries resulting in glomeru-
lar sclerosis and obliteration of capillary lumina. Hyalinosis in
the afferent and efferent arteriolar occurs simultaneously with
the glomerular lesions leading also to tubulointerstitial chronic
changes (44). DN in the transplanted kidney, however, frequently
associate with vascular and tubulointerstitial changes caused by
allograft rejection, viral infection, or CNI nephrotoxicity, which
differentiates it from the DN in the native kidney.
In spite of the extensive data on the pathways that lead to DN in
the native kidney, there is still a paucity of such data on DN after
kidney transplantation. Although, we believe that the same mech-
anisms lead to DN in native kidney contribute to the development
of post transplant DN, there have been no studies confirming
these mechanisms in the transplanted kidney. However, there are
few pathways that have been described in the initiating and devel-
oping of DN; these may have some significance in the transplanted
kidney. Herein, will discuss two of these pathways.
Recently, there have been major changes in our understanding
of DN development in the native kidney, with a major focus on the
podocyte as the initial site of injury (45), which leads later to the
progression of the classic changes of diabetic nodular glomerular
sclerosis and interstitial fibrosis.
In a recent study by Fiorina et al., the investigators described
the role of podocyte B7-1 in the podocyte injury that results from
hyperglycemia (46). The authors found that B7-1 upregulation
was induced by hyperglycemia; this upregulation was found to
be mediated by activation of the 110-kDa catalytic PI3Kα sub-
unit. Furthermore, the addition of CTLA4-Ig such as abatacept
prevented cytoskeleton disruption and adhesion in podocytes that
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were exposed to hyperglycemia in vitro (46). This data can be of a
significant importance in kidney transplantation field. Belatacept,
a newer CTLA4-Ig with higher affinity to B7-1 has been approved
recently as a maintenance immunosuppressive therapy in kidney-
transplant. Hence, it will be of a great interest to evaluate the effect
of belatacept in preventing the developing of DN after kidney
transplantation.
A second pathway that has been described as a possible con-
tributor to the development and progression of DN in the native
kidney is the mTOR. Recent studies suggested that the mTOR
pathway of the podocytes plays an important role in the under-
lying mechanisms of the progression of glomerular diseases (47)
and DN (48). In a recent data by Gödel et al., the investigators
confirmed that mTOR complex (mTORC) 1 and 2 have crucial
roles in the podocyte function. Deletion of mouse podocytes
mTORC 1 and 2 induced significant proteinuria and lead to
the progression of glomerulosclerosis (48). On the other hand,
patients with DN have a significant activation of the podocytes
mTOR that associated with early glomerular hypertrophy and
hyperfiltration (48). Therefore, there is a potential utilization
of mTOR inhibitors such as rapamycin in the prevention of
developing DN. Rapamycin has been in use for many years as
a maintenance immunosuppressant to prevent kidney-transplant
rejection.
A third pathway implies the role of circulating factors that are
known to be involved in causing proteinuria. For example, cir-
culating soluble urokinase plasminogen activator receptor uPAR
(suPAR) that is known as one of the culprits in native and recur-
rent Focal and Segmental Glomerulosclerosis (FSGS) has recently
been shown to play an active role in patients with DN (49). There,
increased suPAR serum levels cause podocyte apoptosis through
its association with acid sphingomyelinase-like phosphodiesterase
3b (SMPDL3b) on podocytes. Additional clinical studies further
support this concept showing that suPAR is a predictor of protein-
uria in patients with DM (50). The neutralization of suPAR may
thus be a novel approach to treat DN in the native and possibly
also in the transplanted kidney.
MANAGEMENT OF NODAT
The management of NODAT requires a multifaceted approach
given that this condition affects multiple organs other than the
allograft itself. Other than extensive counseling of pre-transplant
patients regarding the higher odds of developing NODAT (espe-
cially in high risk groups, as outlined above) and recommenda-
tion for implementation of general pre-transplant measures (like
weight loss, physical activity, and dietitian referral), most of the
transplant centers in the United States have abandoned the screen-
ing of transplant recipients with oral glucose tolerance test as this
would possibly affect the candidacy for transplantation. Post trans-
plantation screening for NODAT is, however, recommended for
all solid organ recipients. Namely, most of the transplant centers
would screen the recipients after transplant with weekly fasting
glucose testing in the first month after transplantation and con-
tinue screening at 5, 6, and 12 months. After this period even
though the risk of NODAT is somewhat lower, at least yearly
testing with either glycosylated hemoglobin or fasting glucose is
recommended.
Early diabetes specialist referral, adequate glycemia control as
well as treatment of comorbid conditions remain the backbone
of medical approach to this condition. Further, good control of
glycemia may even decrease the risk for rejection (51). In patients,
who develop DN with overt micro and macroalbuminuria, strict
glycemia control in addition to the use of angiotensin inhibitors
and statins remains strongly recommended. In transplant patients
other than the aforementioned measures extrapolated from the
general population, the benefit of decreasing immunosuppres-
sion with respect to NODAT prevention and treatment should
be carefully weighted against the risk of provoking a rejection
in the allograft. Switching from one class of immunosuppressive
medication to other should be individualized since the more dia-
betogenic transplant medications may have other advantages to
the longevity of the allograft compared to their competitors.
OUTCOME OF KIDNEY-TRANSPLANT RECIPIENTS WITH
NODAT
Even though the two main causes of kidney-transplant loss are
chronic allograft nephropathy and death with a functioning allo-
graft, NODAT is strongly associated with impaired patient survival
(6, 52) as well as increased cardiovascular mortality (52, 53). Stud-
ies demonstrate that kidney-transplant recipients with NODAT
are at a two- to three-fold increased risk of fatal and non-fatal car-
diovascular disease events as compared with non-diabetic patients
(53, 54). In addition, large retrospective registries have concluded
that NODAT is a strong, independent predictor of global mortality,
graft failure, and death-censored graft failure (6).
The mechanism by which NODAT influences the allograft sur-
vival is not well understood, other than predisposing patients to
recurrent infections and acute rejection especially when attempts
are made to decrease immunosuppression in order to minimize
the diabetogenic effect of medications like TAC. In addition to
this, NODAT likely contributes to recurrence of DN in the allo-
graft. Similar to the general population, diabetic complications are
also commonly encountered in patients with NODAT including
ketoacidosis, neurologic, and ophthalmic complications as well as
recurrent hypoglycemia and shock (55).
SUMMARY
In summary, NODAT is a common and serious condition that
affects the overall health and the survival of a transplant recipient.
Inability to control NODAT is associated with significant allograft
failure as well as overall transplant recipient morbidity. Strenuous
efforts must be undertaken to minimize its detrimental effect on
the comorbid conditions that develop as a consequence of NODAT.
We are looking forward to newer transplant protocols and med-
ications that do not have the diabetogenic side effects of the ones
currently used among the transplant patients and many such are
currently underway.
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